Florida stem-cell rules: state provisions and federal requirements

For someone living with joint pain, the idea of helping damaged tissue repair itself is compelling. Stem-cell research draws on that hope. But “stem cells” describes a broad family of approaches, and the treatment offered by one clinic may be very different from the product tested in a promising study.

Florida’s law, effective July 1, 2025, allows physicians to provide specified stem-cell therapies related to orthopedics, wound care or pain management under state conditions. Understanding what those conditions cover helps put a treatment offer in context. [1] [2] [3]

What Florida’s law covers

The provisions apply to defined cell and tissue products and treatment within the physician’s scope of practice. They include sourcing, quality, advertising and consent requirements. They do not create a general authorization for anti-aging infusions or whole-body rejuvenation. [1] [2]

A useful conversation therefore starts with a specific health problem. Is the aim to relieve knee pain, help a wound heal or address another condition? The provider should explain how the exact product and intended use fit the applicable rules.

Why the federal position still matters

FDA classification depends on what a product contains, how it is processed and what it is intended to do. Some human cell and tissue products can be used under a tissue framework without premarket product approval, but only if they meet all relevant criteria. These include limited processing and use for the same basic function the tissue performed in the donor. Other products need the relevant drug, biologic or device authorization. [4]

Florida’s state permission does not itself supply that federal authorization. Nor does an “FDA-registered facility” mean that every product it makes is FDA-approved. Registration identifies an establishment; it does not establish the effectiveness of its treatments. [5]

Approved cell therapies do exist. Ryoncil, for example, is a specific donor-derived cell product approved for children aged two months and older with a serious transplant complication called steroid-refractory acute graft-versus-host disease. Its approval belongs to that product and use. It does not validate a different preparation for arthritis or aging. [7] [8]

What quality documentation tells you

Under the Florida provisions, cells must come through a facility with the required FDA registration and regulation, along with qualifying certification or accreditation. The law also requires a report showing live cells after thawing for the relevant product lot, supplied to the physician before use. [1] [2]

These details matter because a biological product’s handling and traceability are part of its quality. They answer questions such as where the cells came from and whether they survived storage. They do not, by themselves, show that the cells will repair cartilage or provide lasting pain relief.

Ask for the product name, source, supplier and the study supporting the proposed use. A study of a different preparation may be interesting background, but it cannot tell you what to expect from the one you would receive.

What knee-arthritis studies show

Two trials illustrate why the details matter. The US MILES trial enrolled 480 people with knee osteoarthritis and compared three cell-based approaches with corticosteroid injections. After one year, none of the cell approaches provided better relief on the study’s main pain measures than the steroid comparison. [9]

Another trial at 15 Indian hospitals tested a different product: cultured bone-marrow cells pooled from donors. It assigned 146 people to the cell product or placebo, with both groups also receiving hyaluronic acid. Its two-year follow-up reported better pain, stiffness and function in the cell group. These later results were secondary study outcomes, and some participants did not complete follow-up. [11]

That improvement in symptoms deserves attention. The scans did not, however, establish better cartilage regeneration in the treated group. Less pain and regrown cartilage are different achievements, and a patient should know which one a study supports.

The trials tested different products, comparisons and groups of patients. Their results can coexist: a favorable finding for one preparation does not erase a disappointing finding for another. Neither supports a general promise that any product labeled “stem cells” will repair a painful joint. [9] [11]

Understanding risks and consent

Biological treatments need careful manufacturing and infection control. In 2018, a CDC investigation linked contaminated umbilical-cord-blood-derived products to infections that hospitalized 12 people, including four in Florida. Contamination was also found in unopened vials. The outbreak demonstrates what can go wrong with particular products; it does not provide a risk percentage for every cell therapy. [12]

FDA has also warned about serious harms reported with unapproved regenerative products. The type of product, route of administration and quality controls all affect the questions to ask. A small study without a serious complication cannot rule out rare or delayed problems. [6]

For physicians covered by the Florida provisions, advertising must prominently disclose the lack of FDA approval, and patients must give signed consent after receiving understandable information about expected results, serious risks, benefits and alternatives. The statute includes defined exemptions, so the exact setting matters. [2] [3]

The conversation should leave time to ask what happens if treatment fails, who manages complications and which costs you may face. A trusted primary care clinician or relevant specialist can help compare the proposal with established options.

Keep the hoped-for benefit in view

At Healthy Longevity Clinic, our approach to evaluating treatment evidence starts with the improvement a person hopes to achieve. For someone with knee arthritis, walking more comfortably and managing daily activities matter. We then ask whether the proposed preparation has shown that benefit in comparable people, how long it lasted and what risks accompanied it.

Before deciding, ask four questions: What exactly would I receive? What study supports it for my condition? What is its legal basis for use? Who will provide follow-up and care if something goes wrong?

Cell research has real medical potential. A good decision makes that potential specific enough to examine—and keeps the person’s health, rather than the broad promise of regeneration, at the center.